Compassionate access to new hepatitis C drugs an "emergency" for European patients
Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80%
Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C
Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis
Hep C quad regimens quashed, but some components go forward
Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care
AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1
Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower
Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients
